AstraZeneca's Dato-DXd Shows Improved Survival in Breast Cancer Trial

TL;DR

AstraZeneca's breast cancer drug Dato-DXd shows improved survival in TROPION-Breast02 trial.

AI Summary

AstraZeneca PLC filed a Form 6-K on October 6, 2025, reporting on the TROPION-Breast02 trial. The filing indicates improved overall survival (OS) and progression-free survival (PFS) results for Datopotamab Deruxtecan (Dato-DXd) in patients with previously treated locally advanced or metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer.

Why It Matters

Positive trial results for Dato-DXd in breast cancer could lead to a new treatment option for patients and impact AstraZeneca's oncology revenue.

Risk Assessment

Risk Level: medium — The filing reports positive clinical trial data, which is generally positive, but the ultimate impact depends on regulatory approvals and market adoption.

Key Players & Entities

• AstraZeneca PLC (company) — Registrant
• Datopotamab Deruxtecan (Dato-DXd) (drug) — Investigational treatment
• TROPION-Breast02 (trial) — Clinical trial name

FAQ

From the Filing

0001654954-25-011461.txt : 20251006 0001654954-25-011461.hdr.sgml : 20251006 20251006071850 ACCESSION NUMBER: 0001654954-25-011461 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251006 FILED AS OF DATE: 20251006 DATE AS OF CHANGE: 20251006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251375606 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a1092c.htm DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 a1092c FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of October 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________               AstraZeneca PLC   INDEX TO EXHIBITS     1. Datroway improved OS and PFS in TROPION-Breast02       6 October 2025   Datroway  demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option in TROPION-Breast02   AstraZeneca and Daiichi Sankyo's Datroway is the first and only therapy to significantly improve overall survival vs. chemotherapy in this patient population   Datroway also demonstrated a highly statistically significant and clinically meaningful improvement in the dual primary endpoint of progression-free survival   Positive high-level results from the TROPION-Breast02 Phase III trial showed  Datroway  (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to investigator's choice of chemotherapy as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.   Approximately 70% of patients with metastatic TNBC are not candidates for immunotherapy, including all patients whose tumours do not express PD-L1 as well as patients with PD-L1 expressing tumours who cannot receive immunotherapy due to other factors. 1  Chemotherapy remains the 1st-li